Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EPOPROSTENOL Cause Therapy non-responder? 132 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 132 reports of Therapy non-responder have been filed in association with EPOPROSTENOL (EPOPROSTENOL). This represents 1.0% of all adverse event reports for EPOPROSTENOL.

132
Reports of Therapy non-responder with EPOPROSTENOL
1.0%
of all EPOPROSTENOL reports
45
Deaths
105
Hospitalizations

How Dangerous Is Therapy non-responder From EPOPROSTENOL?

Of the 132 reports, 45 (34.1%) resulted in death, 105 (79.5%) required hospitalization, and 13 (9.8%) were considered life-threatening.

Is Therapy non-responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EPOPROSTENOL. However, 132 reports have been filed with the FAERS database.

What Other Side Effects Does EPOPROSTENOL Cause?

Dyspnoea (2,744) Headache (2,425) Diarrhoea (2,310) Nausea (2,016) Pain in jaw (1,928) Death (1,362) Flushing (1,256) Fatigue (1,133) Hospitalisation (1,078) Vomiting (1,068)

What Other Drugs Cause Therapy non-responder?

ETANERCEPT (3,472) APREMILAST (3,360) METHOTREXATE (2,965) RITUXIMAB (2,731) ADALIMUMAB (2,595) PREDNISONE (2,563) TREPROSTINIL (2,289) INFLIXIMAB (2,122) TOCILIZUMAB (1,775) HYDROXYCHLOROQUINE (1,699)

Which EPOPROSTENOL Alternatives Have Lower Therapy non-responder Risk?

EPOPROSTENOL vs EPTIFIBATIDE EPOPROSTENOL vs EPTINEZUMAB-JJMR EPOPROSTENOL vs EPTINEZUMAB\EPTINEZUMAB-JJMR EPOPROSTENOL vs EQUINE BOTULINUM NEUROTOXIN A/B/C/D/E/F/G IMMUNE FAB2 EPOPROSTENOL vs EQUINE THYMOCYTE IMMUNE GLOBULIN

Related Pages

EPOPROSTENOL Full Profile All Therapy non-responder Reports All Drugs Causing Therapy non-responder EPOPROSTENOL Demographics